Status:
UNKNOWN
Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis
Lead Sponsor:
Addis Ababa University
Collaborating Sponsors:
Ullevaal University Hospital
University of Oslo
Conditions:
Schistosomiasis
Liver Fibrosis
Eligibility:
All Genders
5-60 years
Phase:
NA
Brief Summary
Liver fibrosis is the most serious complication of schistosomiasis mansoni. However only limited proportion of subjects with infection develop this pathology and there is limited knowledge on risk fac...
Detailed Description
Schistosomiasis is the second leading parasitic disease worldwide, after malaria. Liver fibrosis is the most serious complication of schistosomiasis mansoni which can lead to reduced work capacity and...
Eligibility Criteria
Inclusion
- Subjects with schistosomal periportal fibrosis will be eligible for the study
Exclusion
- Subjects with acute malaria, tuberculosis or other chronic diseases such as diabetes mellitus, cardiovascular disease or cancer will be excluded from the study.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
414 Patients enrolled
Trial Details
Trial ID
NCT01260012
Start Date
January 1 2010
End Date
December 1 2015
Last Update
December 15 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aklilu Lemma Institute of Pathobiology, Addis Ababa University
Addis Ababa, Addis Ababa, Ethiopia, 1176